Lifesci Capital Analysts Raise Earnings Estimates for RCKT

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Equities research analysts at Lifesci Capital boosted their Q2 2026 earnings estimates for Rocket Pharmaceuticals in a research note issued to investors on Friday, May 8th. Lifesci Capital analyst P. Dolezal now expects that the biotechnology company will post earnings of $1.02 per share for the quarter, up from their prior forecast of ($0.49). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($1.68) per share. Lifesci Capital also issued estimates for Rocket Pharmaceuticals’ Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.53) EPS and FY2026 earnings at ($0.58) EPS.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). During the same period last year, the business posted ($0.56) EPS.

Several other research analysts have also weighed in on RCKT. Weiss Ratings upgraded shares of Rocket Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Cantor Fitzgerald upped their target price on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Wall Street Zen lowered shares of Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, March 8th. The Goldman Sachs Group upped their target price on shares of Rocket Pharmaceuticals to $3.00 and gave the stock a “sell” rating in a research report on Monday, March 2nd. Finally, Bank of America upped their target price on shares of Rocket Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $11.54.

Rocket Pharmaceuticals Trading Down 1.1%

Shares of Rocket Pharmaceuticals stock opened at $3.59 on Tuesday. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.08. The company’s 50-day simple moving average is $4.06 and its 200-day simple moving average is $3.68. Rocket Pharmaceuticals has a 52-week low of $2.19 and a 52-week high of $7.39. The firm has a market cap of $391.74 million, a price-to-earnings ratio of -1.92 and a beta of 0.52.

Insider Activity

In other news, insider Sarbani Chaudhuri sold 17,650 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $3.84, for a total value of $67,776.00. Following the sale, the insider directly owned 267,510 shares in the company, valued at $1,027,238.40. This represents a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Martin Wilson sold 12,253 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the completion of the sale, the general counsel owned 683,376 shares in the company, valued at $2,261,974.56. This represents a 1.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 47,065 shares of company stock worth $165,174 over the last ninety days. 21.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Prudential Financial Inc. purchased a new position in shares of Rocket Pharmaceuticals during the second quarter valued at approximately $25,000. CANADA LIFE ASSURANCE Co lifted its stake in shares of Rocket Pharmaceuticals by 94.4% during the second quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 5,926 shares during the period. Franklin Resources Inc. purchased a new position in shares of Rocket Pharmaceuticals during the fourth quarter valued at approximately $38,000. Virtu Financial LLC purchased a new position in shares of Rocket Pharmaceuticals during the third quarter valued at approximately $40,000. Finally, Sequoia Financial Advisors LLC purchased a new position in shares of Rocket Pharmaceuticals during the fourth quarter valued at approximately $42,000. Hedge funds and other institutional investors own 98.39% of the company’s stock.

Trending Headlines about Rocket Pharmaceuticals

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: Chardan Capital reaffirmed its Buy rating on Rocket Pharmaceuticals and maintained a $11 price target, implying significant upside from current levels. Article Title
• Positive Sentiment: Lifesci Capital still rates the stock Strong-Buy, even after raising and lowering various 2026 EPS estimates around its latest model update. Article Title
• Neutral Sentiment: Institutional ownership remains high, and several large funds recently increased positions, suggesting some longer-term support for the name. Article Title
• Negative Sentiment: Lifesci Capital trimmed its Q3 2026 and Q4 2026 EPS estimates for Rocket Pharmaceuticals, signaling somewhat weaker expectations for later-year profitability. Article Title
• Negative Sentiment: The company reported a Q1 EPS miss and a wider loss than expected, which has been a key driver behind the recent weakness in the shares. Article Title
• Negative Sentiment: Insider Sarbani Chaudhuri sold 17,650 shares, which can weigh on investor sentiment even though the sale was tied to tax withholding on equity vesting. Article Title

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.